Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Replagal in Treatment-Naïve Fabry Disease
NCT04840667Phase 3Terminated
- Sponsor
- Takeda
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Replacement Enzymes
- Countries
- 8
01
Overview
A Phase 3 trial of agalsidase alfa in Fabry disease (FD), sponsored by Takeda. Started Dec 2021; status: terminated.
02
Drugs
agalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT04840667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04840667.